PTD-DBM
What the Research Actually Shows
Human: 0 studies, 1 groups · Animal: 2 · In Vitro: 2
The cell-penetrating peptide that unlocks the Wnt pathway by blocking CXXC5—connecting DHT, prostaglandin D2, and follicular miniaturization through one therapeutic target, all from a single Korean laboratory
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
PTD-DBM is a synthetic peptide designed to reactivate the growth pathway that balding hair follicles switch off. Here is how it works in plain language: your hair follicles use a signaling system called Wnt to decide whether to grow or rest. In balding areas, a protein called CXXC5 acts as a brake on this system—it physically grabs a key growth protein and shuts the pathway down. PTD-DBM is a decoy that mimics CXXC5 just enough to occupy the grip site, preventing the real CXXC5 from applying the brake. In mice, it accelerated hair regrowth and even helped form entirely new hair follicles in wounded skin. In humans, it has never been tested. Not once. Despite this, you can already buy it online and some clinics apply it to scalps. The science is genuinely interesting. The clinical evidence is zero.
PTD-DBM (Protein Transduction Domain–Dishevelled Binding Motif) is a synthetic peptide designed to target a specific protein-protein interaction in the Wnt/β-catenin signaling pathway—one of the most important biological cascades in hair follicle biology. The compound works by competitive inhibition: it blocks the interaction between CXXC5 (a negative regulator) and Dishevelled (a positive regulator), effectively removing the brake that suppresses Wnt signaling in balding follicles.
The compound emerged from the laboratory of Kang-Yell Choi at Yonsei University in Seoul, where two published studies (2017, 2023) have demonstrated hair regrowth and wound-induced hair follicle neogenesis in mice. The 2023 study connected CXXC5 directly to the DHT→PGD2 signaling axis—placing this single protein at the intersection of the two most validated biological pathways in androgenetic alopecia.
This article examines the mechanism, the preclinical data, the commercial development status, and the gap between what the science suggests and what the evidence proves—which, for PTD-DBM, is the widest gap in Cluster K.
In This Article
Quick Facts: PTD-DBM at a Glance
Type
Synthetic peptide (cell-penetrating peptide + competitive binding motif fusion)
Also Known As
Protein Transduction Domain–Dishevelled Binding Motif, CXXC5-Dvl Interaction Inhibitor
Generic Name
PTD-DBM (no INN or USAN assigned—no regulatory pathway initiated)
Route
Topical (in mouse studies). No established human route. Community use: topical after reconstitution, sometimes with microneedling.
WADA Status
Not listed on Prohibited Lists. No athletic performance application.
Molecular Weight
Estimated ~3–5 kDa (exact MW not disclosed in publications). Larger than most cosmeceutical peptides.
Peptide Sequence
Not fully disclosed. Design: N-terminal protein transduction domain (cell-penetrating sequence) fused to the Dishevelled-binding motif of CXXC5 (competitive inhibitor fragment).
Endogenous Origin
Semi-synthetic. The DBM portion mimics an endogenous protein-protein interaction domain from CXXC5. The PTD is a synthetic cell-penetrating sequence with no endogenous counterpart.
Primary Molecular Function
Competitive inhibition of CXXC5-Dishevelled interaction → prevents CXXC5-mediated suppression of Wnt/β-catenin pathway → de-represses β-catenin nuclear translocation → transcription of hair growth genes (LEF1, cyclin D1, ALP)
Active Fragment
The DBM (Dishevelled-Binding Motif) is the pharmacologically active portion. The PTD enables membrane penetration—delivery function, not therapeutic function.
Brand Name
None. CK Regeon (formerly CK Biotech) holds commercial rights. No consumer product launched.
Related Compound Relationship
No direct relatives in the peptide space. Valproic acid (a GSK-3β inhibitor) showed synergy with PTD-DBM in the original study. KY19382 is a small-molecule CXXC5-Dvl inhibitor in development by CK Regeon—potentially a non-peptide successor.
Clinical Programs
Zero. No IND filed. No clinical trial registered on ClinicalTrials.gov. CK Regeon raised $12M Series B (2021) but has not initiated human studies as of April 2026.
Community Interest
Growing. PTD-DBM is available from research peptide vendors (lyophilized, 5–10 mg vials). Some clinics and med spas offer topical PTD-DBM scalp protocols despite zero human data. Marketed as "next-generation Wnt activator" in biohacker communities.
FDA Status
Not approved. Not submitted. Not in clinical development. No regulatory pathway initiated.
Half-Life
Unknown. No pharmacokinetic data in any species. Cell-penetrating peptides generally have short plasma half-lives (minutes) but may have longer tissue residence times.
Evidence Tier
4 Preclinical Only
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is PTD-DBM?
Pronunciation: pee-tee-dee dee-bee-em
Inside every hair follicle, a signaling pathway called Wnt/β-catenin controls the fundamental decision: grow or rest. When Wnt is active, follicular stem cells proliferate, dermal papilla cells secrete growth factors, and the follicle builds a hair. When Wnt is suppressed, the follicle miniaturizes, rests, and eventually stops producing visible hair. Androgenetic alopecia—the most common form of hair loss—is, at its core, a disease of progressive Wnt suppression in the follicle.
The body has built-in brakes on the Wnt pathway to prevent uncontrolled growth (uncontrolled Wnt is a hallmark of several cancers). One of these brakes is a protein called CXXC5 (CXXC-type zinc finger protein 5). CXXC5 physically binds to Dishevelled (Dvl), a protein that sits upstream of β-catenin in the Wnt cascade. When CXXC5 grabs Dishevelled, it prevents Dishevelled from doing its job—relay the growth signal—and the pathway shuts down.
In balding scalps, CXXC5 is overexpressed. Too much brake. Not enough growth signal. The Kang-Yell Choi laboratory at Yonsei University in Seoul engineered a peptide to solve this problem. PTD-DBM is a two-part molecule: the DBM (Dishevelled-Binding Motif) mimics the portion of CXXC5 that grabs Dishevelled, competing with the real CXXC5 for the binding site. The PTD (Protein Transduction Domain) is a cell-penetrating sequence that allows the peptide to cross cell membranes without needing a receptor.
The result, in mice: Wnt signaling is de-repressed, follicular stem cells reactivate, and hair regrows. In wounded mouse skin, the combination of PTD-DBM and valproic acid even induced the formation of entirely new hair follicles—a process called wound-induced hair follicle neogenesis.
PLAIN ENGLISH
Your balding follicles have a protein (CXXC5) that acts like an overactive brake on the growth signal. PTD-DBM is a decoy that blocks the brake from engaging, letting the growth signal run normally again. In mice, this caused hair to regrow—and in wounded skin, entirely new follicles formed. In humans, it has never been tested.
Origins and Discovery
The PTD-DBM story begins with a basic science question: what suppresses Wnt signaling in balding hair follicles? The answer came from the Choi laboratory at Yonsei University, where researchers had been studying CXXC5's role in various tissues. CXXC5 had been characterized as a Wnt pathway feedback inhibitor—part of the pathway's built-in self-regulation mechanism. The Choi group asked whether CXXC5 was overexpressed in androgenetic alopecia and whether disrupting its interaction with Dishevelled could reactivate follicular Wnt signaling.
The landmark 2017 publication in the Journal of Investigative Dermatology (Lee et al., PMID 28595998) answered both questions. CXXC5 was indeed overexpressed in human balding scalp tissue (confirmed by immunohistochemistry on human samples—the only human-derived data in the entire PTD-DBM evidence base). CXXC5 knockout mice showed accelerated hair regrowth. And a synthetic peptide designed to competitively inhibit the CXXC5-Dishevelled interaction—PTD-DBM—reproduced the knockout phenotype in wild-type mice.
The paper generated significant attention in both the scientific community and the hair loss consumer space. CK Biotech (now CK Regeon), a spin-off company from the Choi laboratory, raised $12 million in Series B funding in 2021 to commercialize the technology. Media coverage described PTD-DBM as a potential "cure for baldness."
As of April 2026, CK Regeon has not registered a clinical trial. The company's pipeline includes KY19382, a small-molecule CXXC5-Dvl inhibitor that may represent a pivot from the peptide format to a more pharmaceutically conventional drug candidate. PTD-DBM itself remains a preclinical compound—sold by research vendors but tested only in mice.
Mechanism of Action
The Wnt/β-Catenin Pathway in Hair
The Wnt/β-catenin pathway is the master regulatory cascade for hair follicle biology. When Wnt ligands bind their receptors (Frizzled family), they activate Dishevelled, which inhibits the GSK-3β destruction complex. This allows β-catenin to accumulate in the cytoplasm, translocate to the nucleus, and activate transcription of target genes—including LEF1 (hair follicle differentiation), cyclin D1 (cell proliferation), and alkaline phosphatase (DPC functionality marker).
In androgenetic alopecia, Wnt signaling is progressively suppressed in miniaturizing follicles. This suppression is multifactorial, but CXXC5 overexpression is a newly identified contributor: excess CXXC5 protein binds Dishevelled and prevents it from relaying the Wnt signal, effectively short-circuiting the pathway at an early step.
CXXC5 as Negative Regulator
CXXC5 normally serves as a negative feedback mechanism: when Wnt activates β-catenin signaling, one of the genes upregulated is CXXC5 itself. CXXC5 then binds Dishevelled and dampens the signal—a classic biological thermostat. The problem in androgenetic alopecia is that this thermostat is stuck in the "off" position. CXXC5 is overexpressed beyond normal feedback levels, chronically suppressing Wnt below the threshold needed for healthy hair cycling.
The DHT→PGD2→CXXC5 Axis
The 2023 study (Seo et al., PMID 36831222) connected CXXC5 to the two most validated pathways in androgenetic alopecia:
DHT (dihydrotestosterone)—the androgen directly implicated in follicular miniaturization—upregulates PTGDS (prostaglandin D synthase) in dermal papilla cells. PTGDS produces PGD2 (prostaglandin D2), the same lipid mediator identified by Garza et al. (2012) as elevated in balding scalps and inhibitory to hair growth. PGD2 then induces CXXC5 expression, which suppresses Wnt.
This cascade places CXXC5 at the convergence point: DHT → PGD2 → CXXC5 → Wnt suppression → miniaturization. PTD-DBM disrupts the final step—preventing CXXC5 from engaging Dishevelled—which theoretically bypasses both the androgen and prostaglandin signals in a single intervention.
PLAIN ENGLISH
The hormone DHT (which finasteride blocks) raises levels of PGD2 (a fat molecule elevated in bald scalps), which raises levels of CXXC5 (the Wnt pathway brake). PTD-DBM blocks the brake at the very end of this chain. In theory, this single peptide could counteract both DHT and PGD2 effects on the follicle—without needing to block either one directly.
Competitive Inhibition Mechanism
PTD-DBM works by molecular mimicry. The DBM portion of the peptide reproduces the structural features of CXXC5's Dishevelled-binding domain. When PTD-DBM enters a cell (via the PTD's membrane-penetrating activity), it competes with endogenous CXXC5 for the Dishevelled binding site. At sufficient concentration, PTD-DBM outcompetes CXXC5, freeing Dishevelled to relay the Wnt signal normally.
This is a more targeted approach than direct Wnt activators (like lithium chloride or valproic acid), which stimulate the entire pathway indiscriminately. PTD-DBM only removes one specific inhibitor—preserving the rest of the pathway's regulatory architecture. Whether this selectivity provides a meaningful safety advantage in practice is unknown.
Wound-Induced Hair Follicle Neogenesis
The most dramatic finding in the PTD-DBM literature: in wounded mouse skin, PTD-DBM combined with valproic acid (a GSK-3β inhibitor that directly activates Wnt) induced the formation of entirely new hair follicles—not regrowth of existing follicles, but de novo folliculogenesis. This process, called wound-induced hair neogenesis (WIHN), is extremely rare in adult mammalian skin. If reproducible in humans, it would represent a fundamentally different therapeutic paradigm from any existing hair loss treatment.
The caveat: WIHN has been demonstrated only in mouse wound models. Whether adult human skin can form new follicles under any conditions remains debated. Mouse skin has fundamentally different regenerative capacity than human skin.
Key Research Findings
Landmark Study: CXXC5-Dvl Disruption (Lee et al., 2017 — PMID 28595998)
Published in the Journal of Investigative Dermatology, this study established the entire PTD-DBM paradigm. Key findings across multiple experimental models:
Human tissue: CXXC5 immunoreactivity was confirmed in miniaturized follicles and arrector pili muscles of human balding scalps by immunohistochemistry. This is the only human-derived data in the PTD-DBM evidence base—it confirms the target exists in human alopecia but does not test the compound in humans.
CXXC5 knockout mice: Hair regrowth after depilation was significantly accelerated in CXXC5⁻/⁻ mice compared to wild-type controls. When combined with valproic acid, the effect was enhanced further. This genetic proof-of-concept demonstrates that removing CXXC5 function improves hair growth—the biological rationale for PTD-DBM.
PTD-DBM in wild-type mice: Topical PTD-DBM activated Wnt/β-catenin signaling in skin (measured by β-catenin accumulation and ALP activity) and accelerated hair regrowth after depilation. The effect phenocopied the CXXC5 knockout—confirming that the peptide mimics the genetic loss of CXXC5 function.
Wound-induced neogenesis: PTD-DBM + VPA combination induced new hair follicle formation in full-thickness wound sites—a dramatic result suggesting the combination can activate follicular morphogenesis programs in adult mouse skin.
Follow-Up: DHT-PGD2-CXXC5 Axis (Seo et al., 2023 — PMID 36831222)
Published in Cells, this study connected CXXC5 to the androgen and prostaglandin pathways:
DHT treatment of dermal papilla cells upregulated PTGDS and PGD2 production. PGD2 treatment induced CXXC5 expression and suppressed Wnt target genes (β-catenin, ALP, BMP2). In mice, PGD2-induced hair loss was rescued by CXXC5 knockout or PTD-DBM treatment. PTD-DBM also overcame PGD2-mediated suppression of wound-induced hair neogenesis.
This study strengthens the mechanistic rationale by placing CXXC5 downstream of DHT and PGD2—two independently validated hair loss mediators—and confirming that PTD-DBM can rescue the endpoint (hair loss) regardless of which upstream signal is driving CXXC5 overexpression.
Safety Profile
No Human Safety Data
PTD-DBM has never been administered to a human in a clinical setting. All safety inferences are extrapolations from mouse studies and theoretical considerations.
Preclinical Safety
The Lee et al. (2017) and Seo et al. (2023) mouse studies reported no adverse effects from topical PTD-DBM application. However, these were short-term efficacy studies, not systematic toxicology assessments. Comprehensive safety evaluation—single-dose toxicity, repeat-dose toxicity, genotoxicity, carcinogenicity, reproductive toxicity—has not been published.
Wnt Pathway and Cancer Risk
This is the most important theoretical safety concern. The Wnt/β-catenin pathway is one of the most frequently dysregulated cascades in cancer. Activating mutations in APC, β-catenin, or Axin drive colorectal cancer, hepatocellular carcinoma, and other malignancies. Any compound that activates Wnt signaling—even by removing a single negative regulator—must be evaluated for oncogenic potential.
PTD-DBM's mechanism (removing CXXC5 inhibition) is more targeted than constitutive Wnt activation. The pathway's other negative regulators (APC, Axin, GSK-3β) remain intact. Whether this selectivity provides meaningful cancer safety is unknown and can only be determined by long-term safety studies that do not exist.
Cell-Penetrating Peptide Considerations
The PTD enables membrane penetration in any cell it contacts—not just follicular cells. Topical application limits exposure to skin and underlying tissue, but the distribution of PTD-DBM after topical application (how deep it penetrates, what cell types it reaches, whether it enters systemic circulation) has never been characterized. Microneedling protocols would further increase unpredictable tissue distribution.
PLAIN ENGLISH
Nobody knows whether PTD-DBM is safe for humans. The growth pathway it activates (Wnt) is the same one that goes wrong in some cancers. The peptide can enter any cell it touches, not just hair follicle cells. The mouse studies did not find problems, but they were not designed to look for long-term safety issues. Using this compound without clinical safety data is a genuine gamble.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “CXXC5 is overexpressed in human balding scalps” | Immunohistochemistry on human scalp tissue (PMID 28595998) | Supported |
| “PTD-DBM reactivates Wnt signaling in follicles” | Mouse skin: β-catenin accumulation, ALP activity confirmed | Preclinical Only |
| “PTD-DBM accelerates hair regrowth” | Mouse depilation model: faster regrowth in PTD-DBM-treated mice | Preclinical Only |
| “PTD-DBM induces new hair follicle formation” | Wound-induced neogenesis in mouse model (with VPA combination) | Preclinical Only |
| “PTD-DBM works in humans” | Zero human data. Not a single person has been tested in a published study. | Unsupported |
| “CXXC5 connects DHT and PGD2 pathways” | Mouse and in vitro data showing DHT→PTGDS→PGD2→CXXC5 cascade | Preclinical Only |
| “PTD-DBM is safer than direct Wnt activators” | Theoretical argument based on selective mechanism. No comparative safety data in any species. | Theoretical |
| “PTD-DBM + valproic acid is the optimal combination” | Synergy shown in mouse WIHN model. Optimal in mice ≠ optimal in humans. | Preclinical Only |
| “Topical PTD-DBM penetrates human scalp” | The PTD enables cell penetration in vitro. Scalp penetration and follicular delivery: never tested in human skin. | Theoretical |
| “PTD-DBM could replace finasteride” | Mechanistically plausible (acts downstream of DHT signal). Clinically unproven. | Theoretical |
| “Vendor-sold PTD-DBM is the same compound as the lab version” | Vendor purity and identity: unverified by independent analysis. Lab-grade synthesis may differ from vendor production. | Unsupported |
| “CK Regeon will bring PTD-DBM to market” | $12M Series B raised (2021). No clinical trial registered as of April 2026. KY19382 (small molecule) may be the preferred development candidate. | Mixed Evidence |
The Human Evidence Landscape
There is no human evidence for PTD-DBM. None.
The closest thing to human data in the entire PTD-DBM literature is the immunohistochemistry staining of human balding scalp tissue in Lee et al. (2017), which confirmed that CXXC5 protein is present and overexpressed in miniaturized follicles. This validates the target—CXXC5 is relevant to human alopecia—but it does not test the compound in human tissue or human subjects.
No clinical trial has been registered on ClinicalTrials.gov, EudraCT, or any international trial registry. No case report, no compassionate use documentation, no IND application is publicly known. CK Regeon's $12 million in funding has not yet produced a Phase I study.
The entire evidence base consists of two publications from one laboratory (Kang-Yell Choi, Yonsei University), comprising controlled mouse studies and in vitro work with human-derived cells. The studies are well-designed, internally consistent, and published in reputable journals (JID, Cells). But they are unreplicated by independent groups.
PTD-DBM is already commercially available and being applied to human scalps. This is the evidence-practice gap at its most extreme.
Legal and Regulatory Status
PTD-DBM occupies a regulatory void. It is not FDA-approved for any indication. No IND has been filed. No clinical trial is registered. It is not classified as a cosmetic ingredient (no INCI listing), a pharmaceutical, or a dietary supplement.
The compound is sold by research peptide vendors as a "research chemical—not for human use." Some clinics and med spas apply it to patients' scalps regardless, operating in the regulatory gap between research chemical classification and unenforced cosmetic/drug boundaries.
CK Regeon holds intellectual property related to the CXXC5-Dvl interaction target. Whether vendor-sold PTD-DBM infringes on these patents is a legal question beyond Peptidings' scope.
WADA does not list PTD-DBM on the Prohibited List.
Research Protocols
Lee et al., 2017 (JID)
CXXC5⁻/⁻ knockout and wild-type C57BL/6 mice. Hair depilation to synchronize follicles into telogen. Topical PTD-DBM application to dorsal skin. VPA (valproic acid) applied in combination groups. Endpoints: hair regrowth by photography and skin color staging, Wnt signaling by β-catenin immunofluorescence, ALP activity, WIHN quantification in full-thickness wound model. Human balding scalp tissue analyzed by CXXC5 immunohistochemistry.
Seo et al., 2023 (Cells)
C57BL/6 mice treated with PGD2 (subcutaneous injection to scalp region) to induce hair loss. CXXC5⁻/⁻ mice and PTD-DBM-treated wild-type mice as intervention groups. In vitro: HaCaT keratinocytes treated with PGD2 ± PTD-DBM. Endpoints: CXXC5 expression, β-catenin levels, ALP activity, BMP2 expression, WIHN in wound model with PGD2 challenge.
Dosing in Published Research
The following table summarizes dosing protocols for PTD-DBM as reported in published clinical and preclinical research. These reflect study designs, not treatment recommendations.
Mouse Dosing (Lee et al., 2017; Seo et al., 2023)
| Parameter | Detail |
|---|---|
| Route | Topical application to mouse dorsal skin |
| Dose | Not reported in human-translatable units |
| Frequency | Daily (during treatment period) |
| Duration | 14–21 days (depilation model); wound model assessed at 14 days |
| Combination | VPA (valproic acid) applied concurrently in combination groups |
| Species | C57BL/6 wild-type mice; CXXC5⁻/⁻ knockout mice |
No dose-ranging, dose-response, or pharmacokinetic study has been published in any species. The mouse dosing is not translatable to human scalp application.
Dosing — Community Protocols
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
WHY IS THIS SECTION NEARLY EMPTY?
PTD-DBM has limited community usage data. Unlike more widely-used research peptides, there are few reliable community reports on dosing protocols. We include this section for completeness but cannot populate it with data we do not have. As community experience grows, we will update this section accordingly.
WHY NEARLY EMPTY
PTD-DBM has zero published human dosing data. Community protocols are entirely anecdotal—constructed from vendor reconstitution instructions, forum discussions, and clinic marketing materials rather than from any scientific study.
Typical vendor-guided protocol: reconstitute lyophilized PTD-DBM (5 mg vial) in bacteriostatic water, apply topically to scalp, sometimes combined with microneedling (0.5–1.5 mm). Some protocols add valproic acid based on the mouse combination data.
Peptidings does not provide community dosing guidance for PTD-DBM because no dosing has been established in any human study, no safety data exists for human use, and the Wnt-activating mechanism raises cancer-related safety questions that cannot be dismissed without clinical safety evaluation. Self-experimentation with this compound carries risks that are genuinely unknown.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into PTD-DBM combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining PTD-DBM with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
Frequently Asked Questions
Is PTD-DBM the most promising hair loss compound in development?
The mechanistic case is among the most elegant in the hair loss space—a single peptide that addresses the convergence of DHT and PGD2 signaling through one protein-protein interaction. But \u0022most promising mechanism\u0022 and \u0022most promising compound\u0022 are different things. PTD-DBM has zero human data, comes from a single lab, and has not entered clinical trials despite $12 million in funding. Several compounds with less exciting mechanisms have more clinical evidence.
Why hasn't CK Regeon started clinical trials?
We cannot know their internal reasoning. Possible explanations include: formulation challenges (the peptide's estimated 3–5 kDa size is larger than most topical peptides), safety study requirements (Wnt pathway activation requires careful oncogenicity assessment), regulatory strategy considerations, and the development of KY19382 (a small-molecule CXXC5-Dvl inhibitor that may be the preferred clinical candidate over the peptide format).
Can PTD-DBM really create new hair follicles?
In mouse wound models, PTD-DBM + valproic acid induced wound-induced hair follicle neogenesis—the formation of entirely new follicles. This is dramatic and legitimate preclinical data. Whether adult human skin can form new follicles under any conditions remains actively debated. Mouse skin has fundamentally different regenerative capacity. No technology has demonstrated de novo folliculogenesis in adult human skin.
Is the PTD-DBM sold by vendors the same as the lab compound?
Unknown. The exact sequence and synthesis protocol used by the Choi laboratory have not been fully disclosed in publications. Vendor-sold PTD-DBM may or may not replicate the lab compound's structure, purity, and potency. No independent verification has been published. This is a real concern for anyone considering community-sourced PTD-DBM.
What is the cancer risk?
The Wnt/β-catenin pathway is dysregulated in colorectal cancer, hepatocellular carcinoma, and other malignancies. Any compound that activates Wnt—even selectively—raises oncogenic concerns. PTD-DBM removes one negative regulator (CXXC5) while leaving others intact (APC, Axin, GSK-3β), which is theoretically safer than constitutive Wnt activation. But \u0022theoretically safer\u0022 is not the same as \u0022safe.\u0022 No long-term safety study addresses this question.
Should I combine PTD-DBM with valproic acid like the mouse study?
The mouse WIHN data used this combination. Valproic acid is a prescription anticonvulsant with its own safety profile—including hepatotoxicity, teratogenicity, and pancreatitis risk. Self-administering topical VPA based on a mouse study is not a medically supervised decision. We strongly advise against this without physician involvement.
How does PTD-DBM compare to other Wnt activators?
Several compounds activate Wnt signaling: lithium chloride (GSK-3β inhibitor), valproic acid (GSK-3β inhibitor), CHIR99021 (GSK-3β inhibitor). PTD-DBM is unique in that it does not activate Wnt directly—it removes a specific inhibitor. This selective de-repression is theoretically cleaner than direct activation, which overrides all regulatory checkpoints. In practice, no comparative data exists.
Is microneedling with PTD-DBM better than topical alone?
No data informs this question. Microneedling creates channels that improve delivery of topical compounds, but also increases unpredictable tissue distribution—relevant for a cell-penetrating peptide that activates a cancer-associated pathway. The risk-benefit calculation for microneedling + PTD-DBM is entirely speculative.
What is KY19382?
A small-molecule CXXC5-Dvl interaction inhibitor in development by CK Regeon. If successful, it would target the same protein-protein interaction as PTD-DBM but in a more pharmaceutically conventional format—oral or topical small molecule rather than peptide. Small molecules are generally easier to formulate, manufacture, and deliver than peptides. KY19382 may be the version of this technology that eventually reaches clinical trials.
Does the single-lab origin matter?
Yes. In science, independent replication is the gold standard. All PTD-DBM data comes from the Kang-Yell Choi laboratory at Yonsei University. No independent group has published a study confirming the compound's effects on hair growth. The studies are well-designed and published in reputable journals, but unreplicated results carry inherently lower confidence than independently confirmed findings.
Is CXXC5 the reason PGD2 inhibitors haven't worked for hair loss?
Possibly. PGD2 was identified as elevated in balding scalps (Garza et al., 2012), but PGD2 receptor antagonists (like setipiprant) showed disappointing results in early clinical trials. The Seo et al. (2023) data suggests PGD2 may exert some of its hair-inhibitory effects through CXXC5—a pathway that PGD2 receptor antagonists would not address. If CXXC5 induction is PGD2's primary hair-relevant mechanism, then blocking CXXC5 directly (PTD-DBM) would be more effective than blocking PGD2's receptor.
Can I take finasteride and use PTD-DBM?
There is no known interaction, and the mechanisms are complementary (finasteride blocks DHT production; PTD-DBM blocks the downstream CXXC5 brake). However, PTD-DBM has never been tested in humans—alone or in combination. Any use is outside the bounds of clinical evidence, and combining it with prescription medication should involve physician awareness.
Summary of Key Findings
PTD-DBM is the most intellectually exciting compound in Cluster K and the one with the least clinical evidence. The mechanism is genuinely novel: a single peptide that disrupts the CXXC5-Dishevelled interaction, de-repressing Wnt/β-catenin signaling at the convergence point of the androgen and prostaglandin pathways. The mouse data is compelling—hair regrowth, Wnt reactivation, and in wounded skin, entirely new follicle formation.
The gap between mechanism and evidence is the widest in the cluster. No human has been tested. No clinical trial has been registered. The entire evidence base comes from one laboratory. The compound is estimated at 3–5 kDa—larger than typical cosmeceutical peptides, raising delivery questions. The Wnt-activating mechanism carries theoretical cancer risk that cannot be dismissed without safety data.
And yet PTD-DBM is already available from vendors and applied in clinics—a case study in how commercial availability outpaces clinical validation in the peptide space. The compound's future may lie not in the peptide format but in KY19382, the small-molecule successor being developed by CK Regeon.
Verdict Recapitulation
Verdict: Eyes Open. Elegant mechanism targeting a novel and biologically validated pathway. Compelling preclinical data. But single-lab evidence, zero human testing, Wnt pathway cancer concerns, and a company that has raised $12 million without initiating clinical trials. The science deserves attention. The compound does not yet deserve confidence.
For readers considering PTD-DBM, the evidence above represents the current state of knowledge. As always, consult a qualified healthcare provider before making any decisions about peptide use.
Where to Source PTD-DBM
Where to Source PTD-DBM
Every partner listed below has been independently reviewed by Peptidings for product quality, third-party testing, and reputation within the research community. We only recommend sources we’d use ourselves.
A telehealth platform founded by board-certified dermatologists specializing in hair loss. Offers custom-compounded topical and oral treatments including finasteride, dutasteride, and minoxidil combinations — prescribed and personalized by physicians, delivered to your door.
View Treatment Options → ↗Further Reading and Resources
If you want to go deeper on PTD-DBM, the evidence landscape for hair & follicle peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Hair & Follicle Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: PTD-DBM — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Lee SH, Seo SH, Lee DH, Pi LQ, Lee WS, Choi KY. Targeting of CXXC5 by a competing peptide stimulates hair regrowth and wound-induced hair neogenesis. J Invest Dermatol. 2017;137(11):2260-2269. PMID 28595998
- Seo SH, Lee SH, Lee DH, Park JB, Choi KY. CXXC5 mediates DHT-induced androgenetic alopecia via PGD2. Cells. 2023;12(4):555. PMID 36831222
- Kim HY, Yoon JY, Yun JH, Cho KW, Lee SH, Rhee YM, Jung HS, Lim HJ, Lee H, Choi J, Heo JN, Lee W, No KT, Min D, Choi KY. CXXC5 is a negative-feedback regulator of the Wnt/β-catenin pathway involved in osteoblast differentiation. Cell Death Differ. 2015;22(6):912-920. PMID 28967390
- Garza LA, Liu Y, Yang Z, Alagesan B, Lawson JA, Norberg SM, Loy DE, Zhao T, Blatt HB, Stanton DC, Carrasco L, Ahluwalia G, Fischer SM, FitzGerald GA, Cotsarelis G. Prostaglandin D2 inhibits hair growth and is elevated in bald scalp of men with androgenetic alopecia. Sci Transl Med. 2012;4(126):126ra34
DISCLAIMER
PTD-DBM is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 08, 2026. Next scheduled review: October 05, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.